# DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas

> **NCT02633111** · — · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 501 (actual)

## Conditions studied

- B-cell Non-Hodgkin Lymphoma
- Aggressive

## Interventions

- **OTHER:** collected at pre-treatment tumor biopsy
- **OTHER:** Peripheral blood tests
- **DEVICE:** PET/CT

## Key facts

- **NCT ID:** NCT02633111
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-10
- **Primary completion:** 2026-10
- **Final completion:** 2026-10
- **Target enrollment:** 501 (ACTUAL)
- **Last updated:** 2025-11-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02633111

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02633111, "DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02633111. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*